Literature DB >> 34044264

Hypofractionated radiation therapy and wound healing after massive sarcoma resection: Case report and review of the literature.

Michael Allen1, Daniella Silvino2, Mitchell Kamrava3, Wonwoo Shon4, Earl Brien5.   

Abstract

INTRODUCTION: Large high-grade sarcomas are commonly managed with five weeks of pre-operative radiation with chemotherapy followed by surgical resection. Wound complications occur in about one out of three patients with this regimen. Hypofractionated radiation therapy (HFRT) is a developing pre-operative approach that delivers radiation over a shorter duration of 5-10 treatments. PRESENTATION OF CASE: Two patients underwent HFRT with neoadjuvant chemotherapy followed by tumor resection. The first patient had high-grade de-differentiated liposarcoma, and the second patient a high-grade myxofibrosarcoma. Neither patient developed post-operative wound complications despite the massive tumor size. DISCUSSION: Less is understood regarding rates and risk factors associated with wound complications using this shortened radiation approach. With attention to surgical detail, and advancing radiation delivery technologies, rates of complications can be minimized.
CONCLUSION: We discuss our experience with a neoadjuvant hypofractionated chemoradiation protocol in two patients with large volume sarcomas resected from the chest wall and the thigh who did not develop acute wound complications. Further evaluation of this shortened regimen is warranted.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Keywords:  Case report; Hypofractionated radiation; Liposarcoma; Myxofibrosarcoma; Sarcoma

Year:  2021        PMID: 34044264     DOI: 10.1016/j.ijscr.2021.106005

Source DB:  PubMed          Journal:  Int J Surg Case Rep        ISSN: 2210-2612


  1 in total

1.  First-Line Anlotinib Combined with Stereotactic Body Radiation Therapy for an Octogenarian with Pulmonary Carcinosarcoma.

Authors:  Long Liang; Taiyu Chen; Tao Ren; Mian Mao; Keli Wang; Chunhan Tang; Juan Xiao; Hongyuan Jia; Wenli Chen; Qifeng Wang; Tao Li
Journal:  Cancer Manag Res       Date:  2022-01-06       Impact factor: 3.989

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.